Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2016-08-11

FDA Approved: ATROVENT HFA — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Atrovent HFA (ipratropium bromide) submitted by Boehringer Ingelheim Pharmaceuticals, Inc., indicating an update…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ATROVENT HFA (IPRATROPIUM BROMIDE)

Snippet

SUPPL AP for ATROVENT HFA (IPRATROPIUM BROMIDE)